Several clinical trials have demonstrated the efficacy and safety of Myocet in treating metastatic breast cancer. These studies have shown that Myocet, in combination with other chemotherapy agents, can achieve similar or better therapeutic outcomes compared to conventional doxorubicin, with a significantly lower incidence of cardiotoxicity.
